Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-02-02

Clinical Trial Update: Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial assessing oral miltefosine plus topical paromomycin for American cutaneous leishmaniasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Miltefosine (miltefosine)
  • Paromomycin (paromomycin)

Snippet

Sponsor: Fundacion Nacional de Dermatologia | Conditions: Cutaneous Leishmaniasis, American | Phase 2, Phase 3 | Status: COMPLETED